Loading data for BIAF — first visit, this takes a few seconds.

알림

bioAffinity Technologies ... (BIAF)

NasdaqCM: BIAF · 실시간 가격 · USD

0.40

+0.00 (0.00%)

종가 기준: Aug 21, 2026, 8:00 PM

0.39

-1.75%

애프터마켓: 5:38 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.00% (1D)

데이터 없음

매수호가	0.29
시가총액	3.24M
매출 (ttm)	5.9M
순이익 (ttm)	-15.19M
	-1.05
	-0.09
	n/a
	-0.67
P/B (ttm)	0.72
P/S (ttm)	0.55
실적 발표일	Aug 14, 2025

매도호가	0.47
거래량	916,956
평균 거래량 (20일)	3,261,335
시가	0.38
전일 종가	0.40
일중 범위	0.37 - 0.42
52주 범위	0.33 - 13.50
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BIAF 소개

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Sep 1, 2022

직원 수 57

상장 거래소 NasdaqCM

티커 BIAF

웹사이트 https://bioaffinitytech.com

전체 기업 정보

재무 실적

2025년 bioAffinity의 매출은 6.11M로, 전년 9.36M 대비 -34.76% 감소했습니다. 순이익은 -14.91M로, 64.93% 증가했습니다.

재무제표

어닝 서프라이즈

bioAffinity가 Nov 14, 2025에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
EPS -4.74 예상치 하회 -2.04, 및 1.25% 전년 대비 성장.

다음 실적 발표

bioAffinity Technologies Inc.의 실적 발표 예정일은 Aug 14, 2025, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · InvestorsHub

bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung

bioAffinity Technologies, Inc. (NASDAQ:BIAF) has signed a nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung, giving the lung cancer diagnostic access to an establishe...

4주 전 · Zacks

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.

1개월 전 · Zacks

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?

bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.

3개월 전 · Zacks

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung

bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.

4개월 전 · Zacks

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?

BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.

2 페이지 중 1